News and failures from recent treatment trials in systemic sclerosis

by Christopher P. Denton, Philip Yee, Voon H. Ong
Published 2020-10-01

The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis

by Emma Derrett-Smith, Kristina E. N. Clark, Xu Shiwen, David J. Abraham, Rachel K. Hoyles, Olivier Lacombe, Pierre Broqua, Jean Louis Junien, Irena Konstantinova, Voon H. Ong, Christopher P. Denton
Published 2021-09-01

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature

by Emma C. Derrett-Smith, Viktor Martyanov, Cecilia B. Chighizola, Pia Moinzadeh, Corrado Campochiaro, Korsa Khan, Tammara A. Wood, Pier Luigi Meroni, David J. Abraham, Voon H. Ong, Robert Lafyatis, Michael L. Whitfield, Christopher P. Denton
Published 2017-07-01

Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.

by Leslie W Tari, Xiaoming Li, Michael Trzoss, Daniel C Bensen, Zhiyong Chen, Thanh Lam, Junhu Zhang, Suk Joong Lee, Grayson Hough, Doug Phillipson, Suzanne Akers-Rodriguez, Mark L Cunningham, Bryan P Kwan, Kirk J Nelson, Amanda Castellano, Jeff B Locke, Vickie Brown-Driver, Timothy M Murphy, Voon S Ong, Chris M Pillar, Dean L Shinabarger, Jay Nix, Felice C Lightstone, Sergio E Wong, Toan B Nguyen, Karen J Shaw, John Finn
Published 2013-01-01